AV Atazanavir
(Unterschied zwischen Versionen)
(Die Seite wurde neu angelegt: „{{tp|p=32759267|t=2020. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.|pdf=|usr=…“) |
K |
||
Zeile 2: | Zeile 2: | ||
{{tp|p=32857301|t=2020. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.|pdf=|usr=018}} | {{tp|p=32857301|t=2020. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.|pdf=|usr=018}} | ||
{{tp|p=33100379|t=2020. DFT Investigation of Atazanavir as Potential Inhibitor for 2019-nCoV Coronavirus M protease.|pdf=|usr=020}} | {{tp|p=33100379|t=2020. DFT Investigation of Atazanavir as Potential Inhibitor for 2019-nCoV Coronavirus M protease.|pdf=|usr=020}} | ||
+ | {{tp|p=32647771|t=2020. Atazanavir Crystal-Induced Chronic Granulomatous Interstitial Nephritis.|pdf=|usr=}} |
Version vom 11. April 2021, 09:05 Uhr
32759267 2020. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
32857301 2020. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.
33100379 2020. DFT Investigation of Atazanavir as Potential Inhibitor for 2019-nCoV Coronavirus M protease.
32647771 2020. Atazanavir Crystal-Induced Chronic Granulomatous Interstitial Nephritis.